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Introduction
If the World Health Organization (WHO) global maternal 
mortality by cause is examined for the period 1997-2007, 
haemorrhage constitutes 35% of deaths. Published data 
from the triennium 2008-2010 in South Africa indicate that 
if non-pregnancy-related sepsis is excluded, haemorrhage 
still ranks with hypertension as the most common cause of 
maternal deaths (24%). 
So how can anaesthetists improve this situation and save 
lives? Sadly, the main reason for the appalling figures in 
respect of maternal deaths in sub-Saharan Africa is poor 
access to basic obstetric care, blood products and basic 
commodities, such as electricity, for the refrigeration of 
blood and drugs such as oxytocin.1 
Nevertheless, there are many areas where management, 
and hence outcomes, could be improved. This article 
addresses the crucial issues of predicting haemorrhage, 
assessing blood loss, point-of-care monitoring and 
transfusion protocols. Surgical techniques and oxytocic 
therapy are equally important, and are the subject of many 
other reviews.
Predicting increased transfusion 
requirements
The first essential factor in predicting haemorrhage is 
knowledge of the pathology. This is best remembered under 
the headings of the 4 “Ts”: 
•	 Tone (uterine atony or inflammation),
•	 Tissue (placental complications),
•	 Trauma (physical injury or previous trauma),
•	 Thrombin (congenital, or more commonly, acquired 
coagulation abnormalities).2 
The Royal College of Obstetricians and Gynaecologists 
provides odds ratios (ORs) for postpartum haemorrhage 
(PPH) in particular clinical scenarios. Suspected or proven 
placental abruption and placenta praevia constitute the 
highest risk (ORs of 13 and 12, respectively). Multiple 
pregnancies, retained placenta and mediolateral episiotomy 
(OR 5), and pre-eclampsia (OR 4) are next in order. However, 
the anaesthetist should be aware that a large number of 
cases carry an increased risk of major resuscitation since 
the OR for any emergency Caesarean section is 4. 
The incidence of placenta accreta increases with the 
number of Caesarean sections. It rises to > 20% after 
two previous operative deliveries, and to 30% or more 
after 3-4 Caesarean sections.3 Likewise, the requirement 
for hysterectomy increases after two previous Caesarean 
sections in the presence of a major grade of placentae 
praevia.4 
Transfusion requirements are known to be considerable in 
patients with placenta accreta. One paper quotes the use of 
> 10 units of packed cells in 26/66 cases.5 A recent editorial, 
which emphasises the importance of adequate planning 
for Caesarean section for placenta accreta, highlights 
an alarming increase in the condition over the past 
40 years.6 A large retrospective audit in Dublin reports on 
358 hysterectomies associated with 852 379 deliveries. As 
a precipitating cause, placenta accreta increased from 5% 
between 1966 and 1975, to 47% between 1996 and 2005. 
There is no doubt that the increased Caesarean section 
rate is a major contributor to these statistics. Combining 
the predictors of placenta praevia, the number of previous 
Caesarean sections and ultrasound findings may increase 
the sensitivity and specificity of predicting placenta accreta,7 
and by inference, the more dangerous increta and percreta.
Assessment of blood loss
PPH is defined as blood loss of > 500 ml post-vaginal 
delivery, or 1 000 ml post Caesarean section.8 Severe PPH 
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implies >1 500 ml blood loss, at least a 4 U packed cell 
transfusion, a decrease in haemoglobin (Hb) of 4 g/dl, or any 
haemorrhage associated with haemodynamic instability. 
Major haemorrhage involves > 2 500 ml, and massive PPH 
one blood volume or 10 U of packed cells in 24 hours. 
Not only should volume be assessed, but also the rate of 
blood loss. The “rule of 30” is useful. If the patient’s systolic 
blood pressure drops by 30%, the heart rate rises by 30%, 
the respiratory rate increases to more than 30/minute, the 
haemoglobin (Hb) or haematocrit drops by 30%, and the 
urinary output decreases to <30 mL/hour, the patient is likely 
to have lost 30% of her blood volume, and is in moderate 
shock, leading to severe shock. The shock index, defined as 
the heart rate divided by the systolic blood pressure (normal 
up to 0.9 in obstetrics), has been shown in a systematic 
review of the relationship between blood loss and clinical 
signs, to be an accurate indicator of compensatory changes 
in the cardiovascular system due to blood loss. A study 
that examined the accuracy of blood loss estimation after 
simulated vaginal delivery showed that there was a 16% 
underestimation at 300 ml loss, which increased to 41% at 
2 000 ml blood loss.10 Active periodic estimation improves 
the accuracy of the estimation. A pictorial guide to aid visual 
estimation has been published, based on experience at 
Queen Charlotte’s Hospital, London.11 
Monitoring of haemoglobin and 
coagulation
In assessing the specific pathophysiology involved and the 
progress of resuscitation, changes in Hb and parameters of 
coagulation need to be assessed. The HemoCue® device 
(HemoCue America, Brea, USA) and the Rainbow SET® 158 
Radical 7 Pulse CO-Oximeter (Masimo Corporation, Irvine, 
USA) are currently the available point-of-care monitors of Hb. 
The former depends upon the azidmethaemoglobin reaction, 
and the latter applies multiple visible and infrared lights 
from the light emitter to the finger, and then acquires blood 
constituent data based on light absorption. A publication 
from the Stanford University obstetric anaesthesia group 
has shown that when comparing the Pulse CO-Oximeter to 
laboratory values, limits of agreement were unacceptably 
wide.12 In addition, another study compared the HemoCue® 
and the Pulse CO-Oximeter in respect of laboratory 
values, and found that the HemoCue® was associated with 
narrower and more acceptable limits of agreement with 
laboratory values.13 Therefore, current evidence is that the 
HemoCue® is the best available point-of-care device to be 
used in combination with assessments of Hb and acid base 
balance once arterial monitoring has been established early 
in a resuscitation.
New concepts of coagulation depict the formerly separate 
intrinsic and extrinsic pathways as being tightly integrated. 
The tissue factor (extrinsic) pathway initiates thrombin 
generation which triggers the intrinsic elements to generate 
the thrombin burst. Thrombin has a central role, also 
activating factor XIII and stimulating the conversion of 
fibrinogen to fibrin. Feedback regulation of coagulation also 
occurs via thrombin, as well as the thrombolytic pathway. 
Depletion of fibrinogen levels is the central problem in the 
majority of cases of obstetric haemorrhage.  
A survey has shown that standard haemostatic tests 
(prothrombin time and activated partial thromboplastin time) 
did not correlate well with the volume of haemorrhage in 
obstetrics.14 The fibrinogen level correlated best with blood 
loss and was the best marker of a developing coagulopathy. 
In addition, the fibrinogen assay had a long turnaround time. 
Therefore, there is increasing support for the use of point-
of-care monitoring in cases of obstetric haemorrhage, using 
the viscoelastic devices, TEG® (thromboelastography) and 
ROTEM® (thromboelastometry).15 Laboratory coagulation 
tests on plasma end with the formation of fibrin strands, but 
whole blood tests with TEG® and ROTEM® test coagulation 
and also clot strength, stability and lysis. Reference ranges 
have been established for pregnancy using TEG®, showing 
the hypercoagulable state.16 ROTEM® allows for the 
addition of activators and inhibitors, to test various aspects 
of haemostasis. The FIBTEM test is of particular importance 
in obstetric haemorrhage in which the platelet inhibitor 
cytochalasin D is added, which allows an assessment of 
the role of fibrinogen on clot stability.  Once again, reference 
ranges in pregnancy are being established.17 Bedside 
assessment of PPH by ROTEM® has shown decreased 
fibrin-clot quality in PPH, as evidenced by activation at 
5 and 10 minutes, as well as maximum clot firmness.18 
These measures correlate with measured fibrinogen 
levels. A recent investigation found that if fibrinogen was 
measured by point-of-care TEG® instead of the standard 
laboratory method, the use of fibrinogen concentrate would 
be increased and less fresh frozen plasma (FFP) would be 
given.19 Expert opinion is that “transfusion monitoring will 
still require a combination of conventional tests of Hb and 
coagulation, but perhaps with increased use of point-of-
care testing in the future”.20 
Transfusion protocols
Obstetricians and anaesthetists agree that a massive 
transfusion protocol (MTP) is essential in any institution that 
deals with obstetric haemorrhage on a regular basis.21 Some 
investigators recommend that the MTP is initiated when the 
coagulopathy is already advanced.22 A more reasonable 
approach is that of the Stanford group which recommends 
the MTP when uncontrollable haemorrhage or the use of 
> 10 U packed cells is anticipated.23 As yet, there is no 
consensus on the components of the transfusion. There is 
no evidence that the 1:1:1 FFP to red blood cells to platelets 
ratio (as recommended in trauma resuscitation) should be 
applied in obstetrics.  
There is no doubt that fibrinogen occupies a central role 
in the transfusion strategy. Plasminogen and its activators 
are upregulated in early pregnancy, but its inhibitors are 
also enhanced, resulting in increased levels of fibrinogen. 
Fibrinolysis is increased in late pregnancy, and this may 
contribute to decreased levels of fibrinogen after delivery. 
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However, it is not known whether fibrinolysis or rapid 
consumption of fibrinogen is the major contributor to 
hypofibrinogenaemia post-delivery. What is well established 
is that a decrease in fibrinogen is an early predictor of 
severity of PPH. A level of < 2 g/l has a 100% positive 
predictive value for severe PPH.24 Fibrinogen levels vary 
greatly between patients (mean 4.8, range 2.1-9 g/l).25 
Although elevated prepartum fibrinogen levels are not 
associated with a reduced risk of PPH,26 early measurement 
of fibrinogen levels during PPH may be used to predict 
severity.27 A recent study showed that the first fibrinogen 
level and FIBTEM measurement taken after identifying PPH 
predicted the need for a > 4 U packed cells transfusion.  
How should fibrinogen be administered? Practitioners 
should be aware of the contents of the blood products 
that are administered at their institution. Cryoprecipitate, 
the cold insoluble fraction of FFP, contains approximately 
10 times the concentration of fibrinogen as FFP. Therefore, 
while FFP may be useful for volume expansion and for 
the administration of physiological levels of coagulation 
factors, it is not the product of choice for the restoration 
of fibrinogen levels. As a rough guide, in order to raise the 
fibrinogen level by 1 g/l, 30 ml/kg of FFP needs to be given, 
compared with 3 ml/kg of cryoprecipitate. FFP may even 
dilute the fibrinogen during PPH. Fibrinogen concentrate is 
a virally inactivated lyophilised powder that can be stored at 
room temperature. No thawing or blood typing is required. 
When administered in a small volume, this product (not 
yet available in South Africa) rapidly restores fibrinogen 
levels. The Fibrinogen Concentrate as Initial Treatment for 
Postpartum Haemorrhage (FIB-PPH) trial recruited 245 
patients in order to assess whether or not 2 g fibrinogen 
concentrate, used as the first treatment for PPH, reduced 
the requirement for blood transfusion.28 Publication of the 
results is awaited. An excellent recent editorial summarises 
the approach to hypofibrinogenaemia during PPH.29 
What of the use of antifibrinolytics for PPH? WHO care 
pathways for postpartum haemorrhage and retained 
placenta recommend the use of tranexamic acid for 
continued bleeding during uterine atony, uterine rupture 
and lower genital tract trauma. A small unblinded study on 
154 women randomised to receive large-dose tranexamic 
acid versus placebo after > 800 ml blood loss after vaginal 
delivery, showed a statistically, but not clinically, significant 
reduction in blood loss in the tranexamic acid group.30 
The prophylactic administration of tranexamic acid in a 
prospective randomised placebo-controlled trial on 660 
women having Caesarean delivery, showed reduced mean 
blood loss and a reduced risk of massive blood loss in 
the treatment group.31 The World Maternal Antifibrinolytic 
(WOMAN) Trial is in progress.32 Four thousand women are to 
be randomised to receive 1 g tranexamic acid intravenously, 
repeatable once, versus placebo, after 500 ml or 
1 000 ml blood loss after vaginal or Caesarean section 
delivery, respectively. This large trial should resolve 
the issues of both the potential reduction in blood loss 
and mortality by tranexamic acid, as well as possible 
thromboembolic complications.
The role of recombinant activated factor VIIa (rFVIIa) in PPH 
remains highly controversial. rFVIIa was originally thought to 
work mainly through a tissue factor-dependent mechanism. 
It has been discovered that at pharmacological plasma 
concentrations, rFVIIa binds directly to the activated platelet 
and compensates for deficiencies of factor VIIIa and IXa.33 
However, several other coagulation factors are also essential 
for fibrin clot formation. Current recommendations are that 
this agent should only be used after failure with conventional 
therapy.34,35 The dose is 90 µg/kg intravenously over 
3-5 minutes, repeatable once. An adequate haematocrit, 
a platelet count > 50 x 109/l, fibrinogen > 1 g/l, pH > 7.2, 
and temperature > 340C are required. These are difficult 
criteria to achieve during massive obstetric haemorrhage. 
This agent is also extremely costly, and there has been at 
least one literature report of pulmonary embolism after its 
use during PPH.36 It should be remembered that the Royal 
College of Obstetricians and Gynaecologists recommends 
that PPH > 1 l or blood transfusion is an indication for 
subsequent thromboprophylaxis.
Cell salvage
Although it is not a substitute for allogeneic blood transfusion, 
cell salvage has been embraced in the UK as an adjunct 
to acute resuscitation in PPH, and the National Institute 
for Health and Care Excellence guidelines recommend it. 
The risks of amniotic fluid embolism are thought to be very 
low if leucocyte depletion filters are used. Infection is also 
uncommon.37 
A suggested detailed strategy is as follows: 
•	 No strategy of management of PPH is effective without 
early referral, availability and rapid couriering of blood 
products, and a well-defined call-out system of senior 
anaesthetists and obstetricians.
•	 Excessive crystalloids and colloids should be avoided.
•	 A massive transfusion protocol should be initiated 
when >10 U packed cells transfusion is anticipated, or if 
1 500 ml of blood has been lost, and the continuing rate 
of loss remains high and uncontrollable.
•	 Although not proven, a reasonable ratio of blood 
products is red blood cells to FFP to platelets of 6:4:6.
•	 O-negative or group-specific red blood cells should be 
administered.
•	 Ideally, an early estimate should be made of fibrinogen 
consumption or fibrinolysis with ROTEM® or TEG®, and/
or a laboratory assessment of fibrinogen level (Clauss 
test).
•	 No more than 4 U FFP should be infused initially.
•	 Cryoprecipitate (or fibrinogen concentrate, when 
available) should then be administered to maintain 
fibrinogen levels > 1.5 g/l (3 ml/kg raises fibrinogen level 
by 1 g/l).
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•	 The platelet count should be maintained > 50 x 109/l, 
using random donor-pooled platelets.
•	 Tranexamic acid 1 g should be given intravenously, 
repeatable once, until proved otherwise.
•	 A controversial option is recombinant activated factor 
VIIa as a last resort, 90 µg/kg intravenously, repeatable 
once.
Urgent access to definitive care remains a major stumbling 
block in limited-resource areas in the developing world. 
However, recent advances in the prediction and assessment 
of blood loss, a better understanding of coagulation 
mechanisms, point-of-care monitoring and the availability 
of a massive transfusion protocol, should improve the 
efficacy of management of PPH in the labour ward and 
during Caesarean sections. Central to success are the flair 
and leadership skills of the anaesthetist in the co-ordination 
of the resuscitation.  
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